Mertens H G, Lurati M
Dtsch Med Wochenschr. 1975 Jan 10;100(2):45-51. doi: 10.1055/s-0028-1106168.
Azathioprine (150 mg daily) was given to 14 patients with polymyositis. Most of the patients also received prednisolone (initial dose 80-40 mg daily, maintenance dose 15-5 mg daily). Some patients additionally received 6-mercaptopurine, methotrexate and (or) cactinomycin. Symptoms practically disappeared in three patients, while in four there was marked improvement, in four others moderate improvement occurred. Four patients who were improved had previously received long-term treatment with high doses of corticoids but without response. There were three deaths; treatment had definitely failed in one, in the other two the duration of treatment had been too short. Results were best in patients under 40 years of age in whom the disease had followed an acute or subacute course: in two of seven in this group corticoid treatment had previously failed. This fact, as well as the observation of exacerbations when immuno-suppressives were reduced, indicate the value of this form of treatment.
对14例多发性肌炎患者给予硫唑嘌呤（每日150毫克）。大多数患者还接受了泼尼松龙（初始剂量为每日80 - 40毫克，维持剂量为每日15 - 5毫克）。一些患者额外接受了6-巯基嘌呤、甲氨蝶呤和（或）放线菌素。3例患者症状基本消失，4例有明显改善，另外4例有中度改善。4例病情改善的患者此前曾接受大剂量皮质类固醇长期治疗但无反应。有3例死亡；1例治疗肯定失败，另外2例治疗时间过短。40岁以下且疾病呈急性或亚急性病程的患者效果最佳：该组7例中有2例此前皮质类固醇治疗失败。这一事实以及免疫抑制剂减量时病情加重的观察结果表明了这种治疗方式的价值。
